These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 27049263)
1. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein. Liu XY; Liu SP; Jiang J; Zhang X; Zhang T Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells. Xu L; Fu Y; Li Y; Han X Cancer Chemother Pharmacol; 2017 Aug; 80(2):235-242. PubMed ID: 28597042 [TBL] [Abstract][Full Text] [Related]
3. Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway. Li Q; Xue AY; Li ZL; Yin Z Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3520-3526. PubMed ID: 31081108 [TBL] [Abstract][Full Text] [Related]
4. 8-Bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. Yang XH; Zheng X; Cao JG; Xiang HL; Liu F; Lv Y World J Gastroenterol; 2010 Jul; 16(27):3385-93. PubMed ID: 20632440 [TBL] [Abstract][Full Text] [Related]
5. Pentoxifylline induces apoptosis of HepG2 cells by reducing reactive oxygen species production and activating the MAPK signaling. Wang Y; Dong L; Li J; Luo M; Shang B Life Sci; 2017 Aug; 183():60-68. PubMed ID: 28583366 [TBL] [Abstract][Full Text] [Related]
6. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557 [TBL] [Abstract][Full Text] [Related]
7. [Study on the mechanism of DDP-resistance mediated by phosphate JNK in gastric cancer]. Li DW; Peng ZH; Li ZZ; Zhang YH; Zhao MZ; Wu Q Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Mar; 11(2):159-62. PubMed ID: 18344085 [TBL] [Abstract][Full Text] [Related]
8. Metformin and AICAR regulate NANOG expression via the JNK pathway in HepG2 cells independently of AMPK. Shen C; Ka SO; Kim SJ; Kim JH; Park BH; Park JH Tumour Biol; 2016 Aug; 37(8):11199-208. PubMed ID: 26939902 [TBL] [Abstract][Full Text] [Related]
9. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Qin J; Luo M; Qian H; Chen W Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717 [TBL] [Abstract][Full Text] [Related]
10. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Ou Y; Zhai D; Wu N; Li X Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754 [TBL] [Abstract][Full Text] [Related]
12. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells. Zhou Z; Lu X; Zhu P; Zhu W; Mu X; Qu R; Li M Biochem Biophys Res Commun; 2012 Apr; 420(2):336-42. PubMed ID: 22425983 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway. Ye R; Yin L; Ge Y; Zhu X; Xiao Y; Fang C; Liu Q; Zhang H; Li H; Xie B Front Biosci (Landmark Ed); 2024 Aug; 29(8):299. PubMed ID: 39206890 [TBL] [Abstract][Full Text] [Related]
14. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344 [TBL] [Abstract][Full Text] [Related]
15. Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway. Lee HH; Jeong JW; Lee JH; Kim GY; Cheong J; Jeong YK; Yoo YH; Choi YH Oncol Rep; 2013 Sep; 30(3):1257-64. PubMed ID: 23828231 [TBL] [Abstract][Full Text] [Related]
16. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. Chen FS; Cui YZ; Luo RC; Wu J; Zhang H Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900 [TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2. Qu X; Gao H; Zhai J; Sun J; Tao L; Zhang Y; Song Y; Hu T Eur J Pharm Sci; 2020 May; 148():105325. PubMed ID: 32259679 [TBL] [Abstract][Full Text] [Related]
18. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Wu S; Zhang T; Du J Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011 [TBL] [Abstract][Full Text] [Related]
19. Dexamethasone decreases hepatocellular carcinoma cell sensitivity to cisplatin-induced apoptosis. Yang N; Zhang H; Si-Ma H; Fu Y; Zhao W; Li D; Yang G Hepatogastroenterology; 2011; 58(110-111):1730-5. PubMed ID: 21940343 [TBL] [Abstract][Full Text] [Related]
20. Liquiritin inhibits proliferation and induces apoptosis in HepG2 hepatocellular carcinoma cells via the ROS-mediated MAPK/AKT/NF-κB signaling pathway. Wang JR; Li TZ; Wang C; Li SM; Luo YH; Piao XJ; Feng YC; Zhang Y; Xu WT; Zhang Y; Zhang T; Wang SN; Xue H; Wang HX; Cao LK; Jin CH Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1987-1999. PubMed ID: 31956937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]